Insider Trends: Insider at CytoDyn Converts Options in Mist of 90-Day Buying Trend
09:10 AM EST, 02/05/2021 (MT Newswires) -- Dr Scott A Kelly, Director and Chairman & Cmo, exercised options for 166,000 shares in CytoDyn (CYDY) for $124,500 on Feb 05, 2021. Following the Form 4 filing with the SEC, Dr Kelly has indirect ownership of 782,408 company shares, which has a market value of $4.87 million as of the prior-day closing price.
Over the last 90 days, previous to the date of this filing, there have been 2 insider transactions reported to the SEC for CytoDyn. These transactions came from the activity of one insider that resulted in no change to insider holdings with acquisitions exactly offset by dispositions of company shares. Relative to the preceding 90-day window of time, there were 8 transactions from 7 insiders that resulted in the net acquisition of 1,588,300 shares.
This level of transactions is below that of the peer group average in the 324-company Bio Therapeutic Drugs peer group over the last 90-day period. Peer group activity averaged 56.2 transactions per company, with company insiders acquiring on average 24,486 shares.
SEC Story Link http://www.sec.gov/Archives/edgar/data/1175680/000180709421000001/xslF345X03/primary_doc.xml
This report does not constitute a recommendation to purchase or sell any security and the analysts are not registered investment advisors. Further analysis is recommended before undertaking any position in any security. Any risks are solely the responsibility of the buyer/seller. The authors, publishers and distributors of the MT Newswires Live Briefs service and any associates thereof accept no liability for the content or actions taken by anyone or institution utilizing this report.